Basking Biosciences Reports Successful Phase 1 Trial of Stroke Antidote

The Phase 1 trial focused on the safety and efficacy of BB-025, an RNA aptamer designed to specifically bind to and inhibit the activity of BB-031. Subjects received single intravenous bolus doses of the reversal agent, either independently or following the administration of BB-031. Data showed that BB-025 successfully reversed the therapeutic effects of the stroke drug within five minutes, maintaining stability for at least five hours. This rapid-response mechanism is intended to provide clinicians with an immediate safety net should bleeding complications occur or urgent surgery become necessary.

Researchers reported no serious adverse events or deaths during the trial. All recorded side effects, such as infusion-related reactions or minor bleeding, were transient and non-severe. Shahid Nimjee, chief scientific officer at Basking, noted that the results validate the company's approach to creating a durable, controllable stroke intervention. Current standard treatments for acute ischemic stroke reach a limited portion of the patient population, and the company intends to integrate BB-025 into its broader clinical development program for BB-031 following discussions with the FDA.